

Comparison between Same-day Discharge and Overnight stay after Atrial Fibrillation Ablation:  
Systematic Review and Meta-Analysis

Narut Prasitlumkum, MD<sup>1</sup>, Wisit Cheungpasitporn, MD<sup>2</sup>, Ronpichai Chokesuwattanaskul, MD<sup>3,4,5</sup>, Jakrin Kewcharoen MD<sup>6</sup>, Nithi Tokavanich MD<sup>3,5</sup>, Leenhapong Navaravong MD<sup>7</sup>, Krit Jongnarangsin MD<sup>8</sup>

<sup>1</sup>Division of Cardiology, University of California Riverside, Riverside, California, USA

<sup>2</sup>Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA

<sup>3</sup>Division of Cardiovascular Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand

<sup>4</sup>Cardiac Center, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand

<sup>5</sup>Center of Excellence in Arrhythmia Research Chulalongkorn University, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

<sup>6</sup>Department of Internal Medicine, University of Hawaii, Honolulu, HI

<sup>7</sup>Division of Cardiovascular Medicine, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA

<sup>8</sup>Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA

\* Narut Prasitlumkum, MD,

University of California Riverside,

900 University Ave, Riverside, CA 92521

Tel: (951) 827-1012

E-mail: [narutprasitlumkum@gmail.com](mailto:narutprasitlumkum@gmail.com)

Acknowledgement: None

Financial support: None

Conflict of Interest: All authors declare no conflict of interest

Running Head: SDD vs Overnight stay in AF ablation

Word count: 2,792 words

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/pace.14380](https://doi.org/10.1111/pace.14380).

This article is protected by copyright. All rights reserved.

Keywords: Same day discharge, overnight stay, Atrial fibrillation ablation

The data for this systematic review and all potentially eligible studies are publicly available through the Open Science Framework (URL: <https://osf.io/uayp5/>).

#### Abbreviation

AF: Atrial fibrillation

COVID-19: Coronavirus disease2019

GA: General anesthesia

ICE: Intracardiac echocardiogram

RCT: Randomized control trial

RFA: Radiofrequency ablation

TEE: Transesophageal echocardiogram

TIA: Transient ischemic attack

SDD: Same-day discharge

UK: United Kingdom

#### Abstract

**Background:** In the modern era, atrial fibrillation (AF) ablation trend has been shifted toward same-day discharge (SDD), from a traditional overnight stay. Yet, recent studies have not well stated the safety profiles which remained poor-understood and dispersed. We hence performed systematic review and meta-analysis to assess the adverse outcomes of SDD in comparison with an overnight stay.

**Methods:** Databases were searched through January 2021. Effect estimates from the individual studies were extracted and combined using random-effects, generic inverse variance method of Der Simonian and Laird. The primary outcomes included total cumulative complications and immediate complications following AF ablation.

**Results:** Ten observational studies were met our inclusion criteria, comprising of total population of 11,660 patients, with SDD 51.3%. For total cumulative complications, there were no differences observed between SDD and overnight stay (5.2% vs. 6.2%: pooled OR

0.77; 95%CI 0.55 – 1.08,  $p = 0.13$  with  $I^2 = 27.1\%$ ). In addition, comparable immediate complications were also demonstrated (5.2 % vs. 4.3: pooled OR 1.08; 95%CI 0.72 – 1.62,  $p = 0.718$ , with  $I^2 = 37.3\%$ ).

**Conclusion:** Our study suggested that SDD had similar complication rates, both total cumulative and immediate outcomes, compared to overnight stay in selected patients following AF ablation. Nevertheless, randomized control trials are warranted to validate the findings.

## Introduction

In the past decades, a trend toward AF ablation has been significantly rising, reflecting a higher fidelity in this technology.<sup>1</sup> Despite the promising clinical advantageous demonstrated by previous studies<sup>2-4</sup>, higher rates of hospitalization for the procedure have been observed, accompanied by a significant increment in medical cost for hospital stay up to 60%.<sup>5</sup> As an estimated AF prevalence and incidence across all age groups are projected toward 60% worldwide in 2050<sup>6</sup>, the needs of AF treatment, including AF ablation, are subjected to proportionally increasing.

Recently, same-day discharge (SDD) protocol is recommended for elective percutaneous coronary intervention (PCI) if certain criteria are met<sup>7</sup>. This is in response to the emerging of COVID-19, which requires extensive resources and healthcare utilization.<sup>8</sup> With current greater understanding and experience in AF ablation, an outpatient setting for the catheter ablation sounds conducive, feasibly resorting and allaying the impacts of this world great pandemic. Previous studies have suggested potential merits of using SDD protocol, providing medical efficiency while reducing medical expenses.<sup>9,10</sup> Nevertheless, there remains uncertainty in employing this strategy given the lack of standardized protocol and limited data on clinical outcomes.

We hence conducted this comprehensive systematic review and meta-analysis of all relevant data to determine the safety profiles between SDD and overnight stay following AF ablation.

## Methods

### *Protocol registration*

This study was compiled with MOOSE<sup>11</sup> (Meta-analysis of Observational Studies in Epidemiology) statement as described in online supplementary data. The protocol was also registered with PROSPERO (International Prospective Register of Systematic Reviews; - CRD42021231537). Institutional review board approval was not sought because of the use of publicly available cumulative published data.

### *Literature review and Search Strategy*

A systematic literature search of MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews was conducted, retrieving databases from inception to January 2021. Search terms were included “same day discharge”, “day care”, “day case”, “short stay”, “catheter ablation” and “atrial fibrillation”, provided in online supplementary data 1.

### *Study selection*

Citations were stored, and duplicates were removed using the EndNote software (Thomson Reuters, Toronto, Ontario, Canada). Two independent reviewers (N.P. and R.C.) screened the abstracts and titles of the studies and subsequently reviewed the full-text articles for inclusion on the Rayyan (<http://rayyan.qcri.org>) a free web-based and mobile articles screening tool which was designed to screen titles/abstracts for the relevant search terms through academic search engines).<sup>12</sup> No language restriction was limited. A manual search for conceivably relevant studies using references of the included articles was also performed. Authors of the included trials were contacted to clarify unclear information, if necessary. When there were disagreements between the reviewers, we have discussed until we reach a consensus. Newcastle-Ottawa quality assessment scale (NOS) was used to appraise the quality of study for case-control study and outcome of interest for cohort study, as shown in supplementary 3.<sup>13</sup>

### *Inclusion criteria*

1. Study type: Cross-sectional, case-control, cohort studies, or RCT
2. Patient population: Adults > 18 years old undergoing AF ablation
3. Intervention: Discharge on the same day after AF ablation

4. Control: Overnight stay after AF ablation and discharge based on clinician's discretion

5. Outcomes: Total complications

#### *Data extraction and outcome*

Comprehensive data extraction was performed to derive the following information from each study, including title, year of the study, name of the first author, publication year, country where the study was conducted, demographic and characteristic data of subjects, total numbers of participants in each study and discharge protocol (same-day discharge, overnight stay) and total complications. For the most accurate analysis, we utilized OR/RR/HR from multivariable adjustment from studies that contain content of the available data. Otherwise, we extracted absolute numbers provided in each cohort and proceeded with univariate analysis.

First primary outcome: Total complications. It was defined by a summation of any cardiac and noncardiac procedural-related events till the end of follow-up, in which each study was defined, ranging from 30-180 days after patients were discharged.

Second primary outcome: Immediate complications. It was defined by a summation of any cardiac and noncardiac procedural-related events within 48 hours.

Secondary outcome: Total bleeding events, total pericardial conditions, total stroke/TIA, and total phrenic nerve injury.

Exploratory outcomes: In a *post hoc* manner, our decision was made to investigate which factors were associated with successful SDD. Factors included in this study were retrieved directly from reported studies. Not limited to this notice, other potential factors were considered in line with authors' agreement after reviewing inherent studies which described predictors of complications following AF ablation.<sup>14-18</sup> This consensus was constituted based on the assumption that postprocedural complications prevent successful early discharge.

#### *Outcome ascertainment*

For immediate complications detection, routine postprocedural surveillance was performed according to each study's protocol. Routine postprocedural physical exam was

performed by medical providers. All readmission and ER visits medical records were reviewed.

For other complications detection, patients were routinely followed up at the clinics of participating centers in each study. Routine physical exam was performed by medical providers and all relevant medical records, including outpatient follow-up, ER visits, and hospital readmission after the procedure within follow-up periods according to each study.

### *Statistical analysis*

Random-effects model was used to perform meta-analysis given anticipated between-study heterogeneity. Standardized mean differences (SMDs) were used to estimate effect sizes for continuous data. To dichotomize continuous data, if necessary, Hasselblad and Hedges' method was used for conversion, assuming near-normal logistic distribution and equal variance.<sup>19,20</sup> For dichotomous data, generic inverse variance method of Der Simonian and Laird<sup>21</sup> was used to estimate odds ratios (ORs) and 95% CIs. The heterogeneity of effect size estimates across studies was quantified using the Mantel-Haenszel chi-square test and  $I^2$  statistics. Substantial heterogeneity was predefined as  $p < 0.10$  for Mantel-Haenszel chi-square test. The  $I^2$  statistic ranges in value from 0 to 100% ( $I^2 < 25\%$ , low heterogeneity;  $I^2 = 25\%$  to  $50\%$ , moderate heterogeneity; and  $I^2 > 50\%$ , substantial heterogeneity)<sup>13</sup>.

In accordance with Cochrane, publication bias was assessed by evaluation of the symmetry of a funnel plot. Egger's linear regression test and Begg's rank correlation test were used for objective evaluation, of which the presence of publication bias is defined by  $p < 0.05$ . All analysis was performed using STATA version 16 (College Station, TX: StataCorp LLC)

### **Results**

A total of 475 potentially eligible articles were identified through Rayyan<sup>12</sup> using our search strategy. 115 articles were excluded due to duplicated studies. After the exclusion of 217 articles as the inclusion criteria were not fulfilled, there were 28 articles left for full-length review. Fifteen were excluded as no SDD protocol was implemented. One was excluded because patients undergoing AF ablation were excluded. One was excluded as it was only an editorial comment. Lastly, one study was excluded substantial patients who lost

follow-up during the study timeframe. Thus, the final analysis included 10 observational studies (7 retrospective cohort studies, 3 prospective cohort studies).<sup>22-31</sup> The literature retrieval, review, and selection process are demonstrated in **Figure 1**. The characteristics and quality assessment of the included studies are presented in **Table 1**. Selection criteria and definitions of complications from each study were summarized in **Table 2**

### **Study Characteristics and Quality Assessment**

Total populations included in our study were 11,660 (51.3% under SDD protocol and 48.7 under overnight stay). 60.5 % of included studies' populations were female, with an average age of  $61.7 \pm 9.7$  years old. Mean follow-up time was 54 days (range 30-180 days). The proportion of echocardiography-guided catheter ablation usage (ICE/TEE) was extensively varied, from 0 to 100%. Postprocedural echocardiography was routinely employed in the majority of included studies<sup>22,23,27-29</sup> except Akula et al<sup>30</sup> as ICE was already used periprocedurally. For Bartoletti et al, Reddy et al, and Deyell et al<sup>24-26</sup>, echocardiogram was performed only if clinically indicated. It was not clearly specified in Mandragon et al<sup>31</sup> whether routine echocardiogram was used.

In SDD group, only 2.5% (148/5981) was not discharged on the same day as planned. Up to 42.5% (63/148), the reason for prolonging admission was inherently due to procedural-related complications. On the other hand, the rest was nonrelevant to the procedure, including patient's preference, late procedures, and patient's non-procedural medical problems.

Majority of anticoagulation methods were uninterrupted plans. RFA was the main ablation type commonly used (58.8%) in our meta-analysis. Overall mortality rates in this cohort are extremely low ( $< 0.01\%$ ) in both SDD and overnight stay. NOS has ranged from 6 to 8, indicating moderate to high qualities of included studies.

### **Primary outcome**

For total cumulative complications rates, there was no difference between SDD (5.2%) and overnight stay (6.2%) (pooled OR 0.77: 95%CI 0.55 – 1.08,  $p = 0.13$ ). There was moderate heterogeneity in this analysis ( $I^2 = 27.1\%$ ). Similarly, no statistical differences in immediate complications were observed in both protocols (5.2 % in SDD VS 4.3 % in overnight stay; pooled OR 1.08: 95%CI 0.72 – 1.62,  $p = 0.718$ , with moderate heterogeneity ( $I^2 = 37.3\%$ ) (**figure 2**)

## Secondary outcome

Common complications including total bleeding events, total pericardial complications, total stroke/TIA and total phrenic nerve injuries were individually sought. No differences were found between SDD and overnight stay in total bleeding (1.4 % vs. 2.6 %; pooled OR 1.25: 95%CI 0.62 – 2.51,  $p = 0.528$ ), stroke/TIA (0.24 % vs. 0.17 %; pooled OR 1.25: 95%CI 0.41 – 3.73,  $p = 0.709$ ), pericardial complications (0.8% vs. 1.9%; pooled OR 0.64: 95%CI 0.20 – 1.98,  $p = 0.433$ ) and phrenic nerve injuries (0.6% vs. 0.4%; pooled OR 1.26: 95% CI 0.24 – 6.64,  $p = 0.783$ ) (**Figure 3a and 3b**)

## Exploratory analysis

Factors associated with increased likelihood of discharge on the same day were male gender (pooled OR 1.31: 95%CI 1.11 – 1.56,  $p = 0.002$ ), use of conscious sedation (pooled OR 0.26: 95%CI 0.16 – 0.45,  $p < 0.001$ ), and shorter procedural duration (pooled SMD – 3.06 95% CI -4.12 – 2.00,  $p < 0.001$ ). Age (pooled SMD – 0.01: 95%CI -0.14 – 0.12,  $p = 0.870$ ), hypertension (pooled OR 0.93: 95%CI 0.59 – 1.48,  $p = 0.769$ ), previous ablation (pooled OR 0.93: 95%CI 0.51 – 1.69,  $p = 0.807$ ), diabetes (pooled OR 1.07: 95%CI 0.89 – 1.29,  $p = 0.466$ ), cardiomyopathy (pooled OR 0.84: 95%CI 0.51 – 1.38,  $p = 0.490$ ), use of cryoablation (pooled OR 1.80: 95%CI 0.58 – 5.62,  $p = 0.309$ ) and prior stroke (pooled OR 0.77: 95%CI 0.47 – 1.25,  $p = 0.288$ ) were not associated with higher same-day discharge rates.

## Publication bias

Publication bias was not found from funnel plots, Beggs' rank correlation, and Egger's linear regression test for both first and second primary outcomes (**Supplementary file**).

## Discussion

Our systematic review and meta-analysis demonstrated that the SDD protocol for patients undergoing AF ablation was not associated with higher immediate or total procedural complications than an overnight stay. The incidence rates of common complications, including bleeding, pericardial events, stroke/TIA, phrenic nerve injury, and death, were not significantly different in both groups. Moderate heterogeneity was observed given between-study differences, which was anticipated due to varieties in studies' protocols and



methodologies. Of note, the exploratory analyses suggested that male gender, use of conscious sedation, shorter procedural duration were associated with successful discharge on the same day after AF ablation.

Overnight observation is a common practice after AF ablation due to the complexity of the procedure and the need of anticoagulation. Although this convention is reasonable, SDD after AF ablation may render better cost-effectiveness in-hospital resource utilization, especially in the era of COVID-19 pandemic. Recent studies from the UK highlighted considerable annual cost-savings, approximately 98k to 126k\$, in implementing the SDD protocol compared to an overnight stay.<sup>22-24</sup> In our opinion, SDD plan for patients undergoing AF ablation does not only help minimize hospital stays and preserve available beds for sicker patients affected by the current worldwide COVID-19 outbreaks, but also provides an efficient and cost-reduced framework in the future.

Our study showed that total complication rates were not different in both primary and secondary outcomes between SDD and an overnight stay. Total complication rates from our analysis ranged from 3-5%, which were slightly lower than the previous reports.<sup>32,33</sup> The incidence of common complications in our study, especially bleeding events, was reported as low as 1.5-2%. Similarly, the incidence rates of pericardial complication, stroke/TIA, and phrenic nerve injury were extremely low, significantly less than 1%, consistent with recent studies.<sup>33,34</sup> Moreover, mortality rate in our study was found extremely uncommon, < 0.01 %. These findings may stem from tremendous improvement in catheter and 3-dimensional mapping technologies, allowing shorter procedural times and fewer complications.<sup>35,36</sup> Use of echocardiography guided catheter ablation, both TEE and ICE, is another crucial factor that plays a significant role in facilitating shorter procedural duration, fluoroscopy time and doses, as well as fewer complications.<sup>37,38</sup> Direct visualization of cardiac anatomy in several stages during the procedure, especially transeptal puncture, ensures certain positions, mitigating risks of ruptures, tamponade, and pulmonary vein stenosis. The uninterrupted anticoagulation, as well as better postprocedural care, are also considered as one of the main contributions in these findings. Overall, the safety profile of SDD protocol is favorable, readily to be more implemented in clinical practices.

Considering SDD protocols from each study, similar strategies have been adopted, essentially in patients with stable hemodynamic status and the ability to ambulate post-procedurally. Some studies required proximity of patients' residential areas within designated

ranges from hospitals as well as great social supports. Nevertheless, the decision whether patients were discharged or stayed overnight mostly derived from operators' discretion, owing to the absence of standardized guidelines for SDD plans. In our exploratory analysis, it is suggested that male gender, shorter procedural time, and conscious anesthesia are factors favoring SDD. Several studies reported substantially higher complication rates among females compared to males.<sup>33,39,40</sup> We speculate that gender-related anatomical differences, such as smaller heart and vascular structures, as well as smaller body sizes, in females compared to males, may impact the procedures difficulty.<sup>41,42</sup> Catheter manipulation under the limited spaces may theoretically predispose the higher complication risks. For this reason, a longer observation in females is anticipated after AF ablation procedure, as observed in our exploratory analysis. Also, the shorter procedural time and conscious anesthesia may expedite patients' recovery in periprocedural phases and lead to early discharge, especially prior to afternoon time in some studies' protocols.<sup>25,29</sup>

#### Strength and Limitation:

Strengths of our study are as follows. First, this is the first and most comprehensive, and largest systematic review and meta-analysis to provide the current understanding in terms of safety profiles on SDD protocol in comparison with overnight stay. Second, from our pool database, we investigated with our best to explore if any clinical factors could favor successful SDD. Despite the hypothesis-generating context, we believe this information is useful in determining potential candidates for SDD. Third, the generalizability of our analysis well suffices, given a vast diversity in patients demographics, settings, and procedural protocols from included studies.

Yet, this study is imperfectly not without limitations. First, owing to the inclusion of observational studies, residual confounders are inevitable, especially selection bias from pre-defined inclusion criteria of SDD protocol. Nevertheless, our analysis represented the performance of these protocols in the setting of real-world experience, which should exert better practicalities. Second, study heterogeneity was observed. This was expected due to differences in SDD protocols, follow-up duration, use of echocardiography-guided catheter ablation, centers' experience, variations in AF ablation procedures and techniques, periprocedural care, and outcomes definitions. Third, postprocedural echocardiogram protocol was also vastly varying from each study which may result in an underestimated pericardial/intracardiac complication detection. Fourth, satisfactory rates and economic

impacts were not analyzed due to insufficiency of the existing data. Fifth, total complications were non-uniformly defined in each study. We hence decided to assess common complications individually, showing the similar trend with the primary outcome. In addition, our sensitivity analysis, performed by omitting one study each time, confirmed no statistical differences, further verifying robustness of our study.

## Conclusion

Our study encouraged the use of SDD in patients undergoing AF ablation since there are no major differences in complication rates compared to overnight stay. Despite comprehensive analysis of pooled real-world data, further studies, especially RCTs, are needed to confirm the present findings.

## References

1. Kneeland PP, Fang MC. Trends in catheter ablation for atrial fibrillation in the United States. *J Hosp Med.* 2009;4(7):E1-5.
2. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, Noseworthy PA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. *JAMA.* 2019;321(13):1261-1274.
3. Wokhlu A, Monahan KH, Hodge DO, Asirvatham SJ, Friedman PA, Munger TM, Bradley DJ, et al. Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. *J Am Coll Cardiol.* 2010;55(21):2308-2316.
4. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. *N Engl J Med.* 2018;378(5):417-427.

5. Freeman JV, Wang Y, Akar J, Desai N, Krumholz H. National Trends in Atrial Fibrillation Hospitalization, Readmission, and Mortality for Medicare Beneficiaries, 1999-2013. *Circulation*. 2017;135(13):1227-1239.
6. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. *Int J Stroke*. 2021;16(2):217-221.
7. Whiting C, Rao SV, Vidovich MI, Gilchrist IC, Gulati R, Gutierrez JA, Hess CN, et al. 2021 ACC Expert Consensus Decision Pathway on Same-Day Discharge After Percutaneous Coronary Intervention: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2021;77(6):811-825.
8. Bartsch SM, Ferguson MC, McKinnell JA, O'Shea KJ, Wedlock PT, Siegmund SS, Lee BY. The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States. *Health Aff (Millwood)*. 2020;39(6):927-935.
9. Theodoreson MD, Chohan BC, McAloon CJ, Sandhu A, Lancaster CJ, Yusuf S, Foster W, et al. Same-day cardiac catheter ablation is safe and cost-effective: Experience from a UK tertiary center. *Heart Rhythm*. 2015;12(8):1756-1761.
10. Haegeli LM, Duru F, Lockwood EE, Luscher TF, Sterns LD, Novak PG, Leather RA. Feasibility and safety of outpatient radiofrequency catheter ablation procedures for atrial fibrillation. *Postgrad Med J*. 2010;86(1017):395-398.
11. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA*. 2000;283(15):2008-2012.
12. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. *Syst Rev*. 2016;5(1):210.
13. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol*. 2010;25(9):603-605.
14. Spragg DD, Dalal D, Cheema A, Scherr D, Chilukuri K, Cheng A, Henrikson CA, et al. Complications of catheter ablation for atrial fibrillation: incidence and predictors. *J Cardiovasc Electrophysiol*. 2008;19(6):627-631.
15. Steinbeck G, Sinner MF, Lutz M, Muller-Nurasyid M, Kaab S, Reinecke H. Incidence of complications related to catheter ablation of atrial fibrillation and atrial flutter: a

- nationwide in-hospital analysis of administrative data for Germany in 2014. *Eur Heart J*. 2018;39(45):4020-4029.
16. Yang E, Ipek EG, Balouch M, Mints Y, Chrispin J, Marine JE, Berger RD, et al. Factors impacting complication rates for catheter ablation of atrial fibrillation from 2003 to 2015. *Europace*. 2017;19(2):241-249.
  17. Szegedi N, Szeplaki G, Herczeg S, Tahin T, Sallo Z, Nagy VK, Osztheimer I, et al. Repeat procedure is a new independent predictor of complications of atrial fibrillation ablation. *Europace*. 2019;21(5):732-737.
  18. Padala SK, Gunda S, Sharma PS, Kang L, Koneru JN, Ellenbogen KA. Risk model for predicting complications in patients undergoing atrial fibrillation ablation. *Heart Rhythm*. 2017;14(9):1336-1343.
  19. Hasselblad V, Hedges LV. Meta-analysis of screening and diagnostic tests. *Psychol Bull*. 1995;117(1):167-178.
  20. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. *Stat Med*. 2000;19(22):3127-3131.
  21. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7(3):177-188.
  22. Creta A, Ventrella N, Providência R, Earley MJ, Sporton S, Dhillon G, Papageorgiou N, et al. Same-day discharge following catheter ablation of atrial fibrillation: A safe and cost-effective approach. *Journal of Cardiovascular Electrophysiology*. 2020;31(12):3097-3103.
  23. He H, Datla S, Weight N, Raza S, Lachlan T, Aldhoon B, Panikker S, et al. Safety and cost-effectiveness of same-day complex left atrial ablation. *International Journal of Cardiology*. 2020.
  24. Reddy SA, Nethercott SL, Chattopadhyay R, Heck PM, Virdee MS. Safety, Feasibility and Economic Impact of Same-Day Discharge Following Atrial Fibrillation Ablation. *Heart Lung and Circulation*. 2020.
  25. Bartoletti S, Mann M, Gupta A, Khan AM, Sahni A, El-Kadri M, Modi S, et al. Same-day discharge in selected patients undergoing atrial fibrillation ablation. *PACE - Pacing and Clinical Electrophysiology*. 2019;42(11):1448-1455.
  26. Deyell MW, Leather RA, Macle L, Forman J, Khairy P, Zhang R, Ding L, et al. Efficacy and Safety of Same-Day Discharge for Atrial Fibrillation Ablation. *JACC: Clinical Electrophysiology*. 2020;6(6):609-619.

27. Kowalski M, Parikh V, Salcido JR, Chalfoun N, Albano A, O'Neill PG, Bowers MR, et al. Same-day discharge after cryoballoon ablation of atrial fibrillation: A multicenter experience. *Journal of Cardiovascular Electrophysiology*. 2020.
28. Opel A, Mansell J, Butler A, Schwartz R, Fannon M, Finlay M, Hunter RJ, et al. Comparison of a high throughput day case atrial fibrillation ablation service in a local hospital with standard regional tertiary cardiac centre care. *Europace*. 2019;21(3):440-444.
29. Rajendra A, Hunter TD, Morales G, Osorio J. Prospective implementation of a same-day discharge protocol for catheter ablation of paroxysmal atrial fibrillation. *Journal of Interventional Cardiac Electrophysiology*. 2020.
30. D NA, Mariam W, Luthra P, Edward F, D JK, S AL, Alfred S. Safety of Same Day Discharge after Atrial Fibrillation Ablation. *J Atr Fibrillation*. 2020;12(5):2150.
31. Ignacio M, Jarma JJ, Nicolas V, Gustavo D, Leandro T, Milagros C, Vasquez E, et al. Current safety of pulmonary vein isolation in paroxysmal atrial fibrillation: First experience of same day discharge. *Journal of Atrial Fibrillation*. 2018;11(4).
32. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. *Heart Rhythm*. 2017;14(10):e445-e494.
33. Deshmukh A, Patel NJ, Pant S, Shah N, Chothani A, Mehta K, Grover P, et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. *Circulation*. 2013;128(19):2104-2112.
34. Gupta A, Perera T, Ganesan A, Sullivan T, Lau DH, Roberts-Thomson KC, Brooks AG, et al. Complications of catheter ablation of atrial fibrillation: a systematic review. *Circulation Arrhythmia and electrophysiology*. 2013;6(6):1082-1088.
35. Kece F, Zeppenfeld K, Trines SA. The Impact of Advances in Atrial Fibrillation Ablation Devices on the Incidence and Prevention of Complications. *Arrhythm Electrophysiol Rev*. 2018;7(3):169-180.
36. Tripathi B, Arora S, Kumar V, Abdelrahman M, Lahewala S, Dave M, Shah M, et al. Temporal trends of in-hospital complications associated with catheter ablation of atrial fibrillation in the United States: An update from Nationwide Inpatient Sample database (2011-2014). *J Cardiovasc Electrophysiol*. 2018;29(5):715-724.

37. Goya M, Frame D, Gache L, Ichishima Y, Tayar DO, Goldstein L, Lee SHY. The use of intracardiac echocardiography catheters in endocardial ablation of cardiac arrhythmia: Meta-analysis of efficiency, effectiveness, and safety outcomes. *J Cardiovasc Electrophysiol.* 2020;31(3):664-673.
38. Erden I, Erden EC, Golcuk E, Aksu T, Yalin K, Guler TE, Ozcan KS, et al. Impact of transesophageal echocardiography during transseptal puncture on atrial fibrillation ablation. *J Arrhythm.* 2016;32(3):170-175.
39. Kaiser DW, Fan J, Schmitt S, Than CT, Ullal AJ, Piccini JP, Heidenreich PA, et al. Gender Differences in Clinical Outcomes after Catheter Ablation of Atrial Fibrillation. *JACC Clinical electrophysiology.* 2016;2(6):703-710.
40. Kuck KH, Brugada J, Furnkranz A, Chun KRJ, Metzner A, Ouyang F, Schluter M, et al. Impact of Female Sex on Clinical Outcomes in the FIRE AND ICE Trial of Catheter Ablation for Atrial Fibrillation. *Circulation Arrhythmia and electrophysiology.* 2018;11(5):e006204.
41. Dugo D, Bordignon S, Perrotta L, Furnkranz A, Julian Chun KR, Schmidt B. Catheter Ablation of Atrial Fibrillation in Females. *J Atr Fibrillation.* 2013;6(1):893.
42. Salton CJ, Chuang ML, O'Donnell CJ, Kupka MJ, Larson MG, Kissinger KV, Edelman RR, et al. Gender differences and normal left ventricular anatomy in an adult population free of hypertension. A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort. *J Am Coll Cardiol.* 2002;39(6):1055-1060.

## Legends

Fig. 1: PRISMA flow diagram.

**Figure 1**






Fig. 2: Forest plot of the included studies comparing total and immediate complications rates between SDD and overnight stay






Fig. 3a: Forest plot of the included studies comparing bleeding complications and Strok/TIA between SDD and overnight stay



Fig, 3b: Forest plot of the included studies comparing pericardial complications and phrenic nerve injuries between SDD and overnight stay

Author



Supplementary file 1: Search term and publication bias

Supplementary file 2: MOOSE and NOS tables

Table 1: Study characteristics of included studies

**Table 1 study characteristics**

Study (year)	Study type	Country	Total numbers of centers	Total population		Mean age (Years old)	Male (%)	Follow up duration (days)
Akula 2020	Retrospective cohort	USA	Single	ON	145	60.2	60	90 days
				SDD	426	62.3	52	
Bartoletti 2019	Retrospective cohort	UK	Single	ON	642	59 ± 11	68.5	90 days
				SDD	143	59 ± 11	68.1	
Creta 2020	Retrospective cohort	UK	Multicenter	ON	1901	62.9 ± 11.3	60.1	30 days
				SDD	727	61.1 ± 12.5	68.2	

Deyell 2020	Retrospective cohort	Canada	Multicenter	All	3054	60.4 ± 9.5	73.8	30 days	
He 2020	Retrospective cohort	UK	Multicenter	ON	553	59.7 ± 12.1	43	120 days	
				SDD	414	62.5 ± 10.8	45		
Kowalski 2020	Retrospective cohort	USA	Multicenter	ON	1180	66 ± 10	67	30 days	
				SDD	1194	64 ± 11	69		
Mondrago 2018	Prospective cohort	Argentina	Single	ON	137	57.3 ± 12.9	75.2	30 days	
				SDD	58	59.9 ± 10.5	84.5		
Opel 2019	Prospective cohort	UK	Multicenter	ON	276	60 ± 0.8	60	90 days	
				SDD	276	61 ± 0.7	61		
Rajendra 2020	Prospective cohort	USA	Single	ON	41	59.9 ± 12.8	61	90 days	
				SDD	41	58.5 ± 9.9	61		
Reddy 2020	Retrospective cohort	UK	Single	ON	168	60.36 ± 10.0	72.9	180 days	
				SDD	284	60.16 ± 9.9	70.8		

AF: Atrial fibrillation, BMI: Body mass index, Cryo: Cryoballoon ablation, DOACs: Direct oral anticoagulants, DM2: Diabetes mellitus type 2, n/a: not available, ON: Overnight, RFA: Radiofrequency, SDD: Same-day discharge, TIA: Transient ischemic attack, UK: United Kingdom, USA: United States of America

**Table 1 (continued)**

Study (year)	General anesthesia (%)	Use of ICE/TEE guidance	Ablation strategy		Procedural time (minutes)	Prior AF ablation (%)	BMI	Comorbidities	
			RFA (%)	Cryo (%)				Hypertension (%)	DM2 (%)
Akula 2020	n/a	100 % (ICE)	100	0	n/a	n/a	n/a	n/a	n/a
					n/a	n/a	n/a	n/a	
Bartoletti 2019	46.2	Not mentioned	67.6	32.4	153 ± 43	20.6	29.5 ± 5.2	n/a	n/a
	62.5		61.5	38.5	120 ± 29	40.6	29.4 ± 5.0	n/a	n/a
Creta 2020	8.4	30.6 % (Only ICE, no TEE use in this study)	62.6	37.4	150 ± 83	40.4	n/a	n/a	n/a
	34.8		20.8	79.2	79 ± 42	13.8	n/a	n/a	n/a
Deyell 2020	98.7	53.5% (TEE) 0.3 % (ICE)	96.5	3.5	190 ± 69.7	n/a	n/a	39.9	8
He 2020	6	Not mentioned	92.1	6.9	169.2 ± 71.8	15	n/a	n/a	n/a

	2		21.3	78.7	146.2± 80.9	7.7	n/a	n/a	n/a
Kowalski 2020	100	100 %(ICE)	0	100	n/a	n/a	31 ± 6	72	21
							30 ± 6	72	18
Mondrago 2018	100	Not mentioned	n/a	n/a	n/a	19.6	27.7 ± 4.5	59	17
						20	28.4 ± 3.8	24	6
Opel 2019	89	0% (No use of either TEE or ICE)	0	100	63.5± 1.1	0	n/a	61	9
					101.7± 2.9	0	n/a	47	7
Rajendra 2020	100	Not mentioned	100	0	67 ± 22	4.9	29.7 ± 4.6	56.1	2.4
					59 ± 15	7.3	30.1 ± 5.2		
Reddy 2020	60.1	Not mentioned	73.6	22.9	160.76 ± 48.6	28.6	n/a	n/a	n/a
	29.2		57.1	42.9	139.66 ± 37.8	22	n/a		

AF: Atrial fibrillation, BMI: Body mass index, Cryo: Cryoballoon ablation, DOACs: Direct oral anticoagulants, DM2: Diabetes mellitus type 2, ICE: Intracardiac echocardiogram, n/a: not available, ON: Overnight, RFA: Radiofrequency, SDD: Same-day discharge, TEE: Transesophageal echocardiogram, TIA: Transient ischemic attack, UK: United Kingdom, USA: United States of America

Table 2: Summary of selection criteria for SDD of included studies, and definitions of complications

Table 2: Summary of same-day discharge protocol and complications definitions

First author, year	Total participants	SDD Protocol	Definition of complications
Akula, 2020	571	Patients were monitored for at least 6 hours post ablation and were reassessed by the nursing	Death, pericardial tamponade, CVA, hematoma requiring PV stenosis, diaphragmatic paralysis or atriocophageal fistula formation

	<p>staff prior to discharge including inspection of groin access sites. SDD was cancelled if patient had any ablation related complications, non-ablation related medical care or due to patient specific/social reasons.</p>	
<p>Bartolotti, 2019</p>	<p>785 Patients remained on bed rest for 4 hours and were subsequently mobilized in the presence of nursing staff; any bleeding from the femoral access site mandated another hour of bed rest before subsequent mobilization</p>	<p>Not defined</p>

	<p>on. After, patients were offered the choice of either staying overnight or going home in the absence of severe left ventricular dysfunction or a recent history of uncontrolled HF.</p>	
<p>Creta, 2020</p>	<p>2,628</p> <p>Referring physicians identified patients who would not be suitable for SDD prior to the procedure. Patients were monitored for at least 4 hours post ablation. In the absence of clinical concerns, suitable patients were discharged by the nurse with no physician</p>	<p>Death, cardiac tamponade, stroke or TIA, major vascular complications, bradyarrhythmia, persistent PN palsy, air embolus, esophageal fistula, gastroparesis, pharyngeal perforation</p>

		<p>review on the same day using a pre-specified workflow, including evaluation of the femoral access site, observations, national early warning score, electrocardiogram, and symptoms.</p>	
Deyel, 2020	3,054	<p>Patients were monitored for up to 8 hours. Patients were discharged if ambulation was well tolerated with no access site bleeding and vital signs were stable</p>	<p>Access site complication, pericardial effusion, CVA, PN palsy</p>
He, 2020	967	<p>Not reported</p>	<p>Hypotension requiring support, acute pulmonary edema, pericardial effusion/pericardial tamponade stroke, vascular injury/bleeding</p> <p>PN palsy, AV node injury</p>
Kowalski, 2020	2,374	<p>Patients were discharged on the same day</p>	<p>Death, pericardial effusion, TIA, HF, hematoma, PN palsy, pericarditis</p>



		<p>if was cleared by the operator after the procedure based on clinical standards-of care at each hospital with most patients with an intraprocedural complication not eligible for SDD.</p>	
<p>Mondrago Ignacio, 2018</p>	<p>195</p>	<p>Not reported</p>	<p>pericardial effusion requiring intervention, vascular complications, hematoma, PN injury</p>
<p>Opel, 2019</p>	<p>276</p>	<p>Patients were monitored for 4 hours and were discharged if cleared by nurse.</p>	<p>Pericardial effusion or cardiac tamponade, pericarditis, bradycardia, vascular injury, PN injury, air embolus</p>
<p>Rajendra, 2020</p>	<p>82</p>	<p>Prior to procedure, patients needed to be on stable anticoagulation with no bleeding history, acceptable CHA2DS2</p>	<p>Complications involving groin, respiratory, cardiac, or bleeding</p>

	<p>-VAsc stroke risk, BMI &lt; 35, and without systolic HF, respiratory conditions, or interventio nal procedures within 60 days. After the procedure, patient can be discharged home if patients were hemodyna mically stable, in the absence of any complicati ons including groin or respiratory complicati ons, able to ambulate and tolerate liquids/fo d. Confirmati on needed to be made by operator to proceed with SDD.</p>	
--	--	--

<p>Reddy, 2020</p>	<p>448</p> <p>Patients were monitored on bed rest for 2 hours. If groin haemostasis was acceptable and patients were clinically stable after this 2-hour period they could be gently mobilised. If after a further 1-hour observation, there were no evident complications anticoagulation could recommence and the patient could be discharged.</p>	<p>Death, cardiac tamponade, CVA, vascular complications, bradyarrhythmia, PN palsy, air embolus, pulmonary edema, leg numbness, migraine</p>
--------------------	--	---

AV: Atrioventricular; BMI: Body mass index; CVA: Cerebrovascular accident; HF: Heart failure; PN: Phrenic nerve; PV: Pulmonary vein; SDD: Same-day discharge, TIA: Transient ischemic attack

<p>First author, year</p>	<p>Total participants</p>	<p>SDD Protocol</p>	<p>Definition of complications</p>
---------------------------	---------------------------	---------------------	------------------------------------

Akula, 2020	571	Patients were monitored for at least 6 hours post ablation and were reassessed by the nursing staff prior to discharge including inspection of groin access sites. SDD was cancelled if patient had any ablation related complications, non-ablation related medical care or due to patient specific/social reasons.	Death, pericardial tamponade, CVA, hematoma requiring PV stenosis, diaphragmatic paralysis or atriopharyngeal fistula formation
Bartolotti, 2019	785	Patients remained on bed rest for 4 hours and were subsequently mobilized in the presence of nursing staff; any bleeding from the femoral access site mandated another hour of bed rest before subsequent mobilization. After, patients were offered the choice of either staying overnight or going home in the absence of severe left ventricular dysfunction or a recent history of uncontrolled HF.	Not defined
Creta, 2020	2,628	Referring physicians identified patients who would not be suitable for SDD prior to the procedure. Patients were monitored for at least 4 hours post ablation. In the absence of clinical concerns, suitable patients were discharged by the nurse with no physician review on the same day using a pre-specified workflow, including evaluation of the femoral access site, observations, national early warning score, electrocardiogram, and symptoms.	Death, cardiac tamponade, stroke or TIA, major vascular complications, bradyarrhythmia, persistent PN palsy, air embolus, esophageal fistula, gastroparesis, pharyngeal perforation
Deyell, 2020	3,054	Patients were monitored for up to 8 hours. Patients were discharged if ambulation was well tolerated with no access site bleeding and vital signs were stable	Access site complication, pericardial effusion, CVA, PN palsy
He, 2020	967	Not reported	Hypotension requiring support, acute pulmonary edema, pericardial effusion/pericardial tamponade stroke, vascular injury/bleeding  PN palsy, AV node injury
Kowalski, 2020	2,374	Patients were discharge on the same day if was cleared by the operator after the procedure based on clinical standards-of-care at each hospital with most patients with an intraprocedural complication not eligible for SDD.	Death, pericardial effusion, TIA, HF, hematoma, PN palsy, pericarditis
Mondrago Ignacio, 2018	195	Not reported	pericardial effusion requiring intervention, vascular complications, hematoma, PN injury
Opel, 2019	276	Patients were monitored for 4 hours and were discharged if cleared by nurse.	Pericardial effusion or cardiac tamponade, pericarditis, bradycardia, vascular injury, PN injury, air embolus
Rajendra, 2020	82	Prior to procedure, patients needed to be on stable anticoagulation with no bleeding history, acceptable CHA2DS2-	Complications involving groin, respiratory, cardiac, or bleeding

		VASc stroke risk, BMI < 35, and without systolic HF, respiratory conditions, or interventional procedures within 60 days. After the procedure, patient can be discharged home if patients were hemodynamically stable, in the absence of any complications including groin or respiratory complications, able to ambulate and tolerate liquids/food. Confirmation needed to be made by operator to proceed with SDD.	
Reddy, 2020	448	Patients were monitored on bed rest for 2 hours. If groin haemostasis was acceptable and patients were clinically stable after this 2-hour period they could be gently mobilised. If after a further 1-hour observation, there were no evident complications anticoagulation could recommence and the patient could be discharged.	Death, cardiac tamponade, CVA, vascular complications, bradyarrhythmia, PN palsy, air embolus, pulmonary edema, leg numbness, migraine

Study (year)	Study type	Country	Total numbers of centers	Total population		Mean age (Years old)	Male (%)	Follow up duration (days)
Akula 2020	Retrospective cohort	USA	Single	ON	145	60.2	60	90 days
				SDD	426	62.3	52	
Bartoletti 2019	Retrospective cohort	UK	Single	ON	642	59 ± 11	68.5	90 days
				SDD	143	59 ± 11	68.1	
Creta 2020	Retrospective cohort	UK	Multicenter	ON	1901	62.9 ± 11.3	60.1	30 days
				SDD	727	61.1 ± 12.5	68.2	
Deyell 2020	Retrospective cohort	Canada	Multicenter	All	3054	60.4 ± 9.5	73.8	30 days
He 2020	Retrospective cohort	UK	Multicenter	ON	553	59.7 ± 12.1	43	120 days
				SDD	414	62.5 ± 10.8	45	
Kowalski 2020	Retrospective cohort	USA	Multicenter	ON	1180	66 ± 10	67	30 days
				SDD	1194	64 ± 11	69	
Mondrago 2018	Prospective cohort	Argentina	Single	ON	137	57.3 ± 12.9	75.2	30 days
				SDD	58	59.9 ± 10.5	84.5	
Opel 2019	Prospective cohort	UK	Multicenter	ON	276	60 ± 0.8	60	90 days
				SDD	276	61 ± 0.7	61	
Rajendra 2020	Prospective cohort	USA	Single	ON	41	59.9 ± 12.8	61	90 days
				SDD	41	58.5 ± 9.9	61	
Reddy 2020	Retrospective	UK	Single	ON	168	60.36 ± 10.0	72.9	180 days

	cohort			SDD	284	60.16±9.9	70.8		
--	--------	--	--	-----	-----	-----------	------	--	--

Study (year)	General anesthesia (%)	Use of ICE/TEE guidance	Ablation strategy		Procedural time (minutes)	Prior AF ablation (%)	BMI	Comorbidities	
			RFA (%)	Cryo (%)				Hypertension (%)	DM2 (%)
Akula 2020	n/a	100 % (ICE)	100	0	n/a	n/a	n/a	n/a	n/a
					n/a	n/a	n/a	n/a	
Bartoletti 2019	46.2	Not mentioned	67.6	32.4	153 ± 43	20.6	29.5 ± 5.2	n/a	n/a
	62.5		61.5	38.5	120 ± 29	40.6	29.4 ± 5.0	n/a	n/a
Creta 2020	8.4	30.6 % (Only ICE, no TEE use in this study)	62.6	37.4	150 ± 83	40.4	n/a	n/a	n/a
	34.8		20.8	79.2	79 ± 42	13.8	n/a	n/a	n/a
Deyell 2020	98.7	53.5% (TEE) 0.3 % (ICE)	96.5	3.5	190±69.7	n/a	n/a	39.9	8
He 2020	6	Not mentioned	92.1	6.9	169.2± 71.8	15	n/a	n/a	n/a
	2		21.3	78.7	146.2± 80.9	7.7	n/a	n/a	n/a
Kowalski 2020	100	100 %(ICE)	0	100	n/a	n/a	31 ± 6	72	21
							30 ± 6	72	18
Mondrago 2018	100	Not mentioned	n/a	n/a	n/a	19.6	27.7 ± 4.5	59	17
						20	28.4 ± 3.8	24	6
Opel 2019	89	0% (No use of either TEE or ICE)	0	100	63.5± 1.1	0	n/a	61	9
					101.7± 2.9	0	n/a	47	7
Rajendra 2020	100	Not mentioned	100	0	67 ± 22	4.9	29.7 ± 4.6	56.1	2.4
					59 ± 15	7.3	30.1 ± 5.2		
Reddy 2020	60.1	Not mentioned	73.6	22.9	160.76 ± 48.6	28.6	n/a	n/a	n/a
	29.2		57.1	42.9	139.66 ± 37.8	22	n/a		